Inverse agonism at cannabinoid receptors

International Congress Series

Volumn 1249, Issue C, 2003, Pages 75-86

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cannabinoid receptors; G protein sequestration; Inverse agonism; SR141716A; Two state model

Indexed keywords

EID: 21044460152     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(03)00612-5     Document Type: Article

References (59)

1. Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, R.G., International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002), 161–202.
2. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277 (1996), 586–594.
3. Costa, B., Colleoni, M., SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Acta Pharmacol. Sin. 20 (1999), 1103–1108.
4. Pertwee, R.G., Cannabinoids and the gastrointestinal tract. Gut 48 (2001), 859–867.
5. Pinto, L., Izzo, A.A., Cascio, M.G., Bisogno, T., Hospodar-Scott, K., Brown, D.R., Mascolo, N., Di Marzo, V., Capasso, F., Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123 (2002), 227–234.
6. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Huffman, J.W., Layward, L., Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000), 84–87.
7. 1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24 (2001), 198–203.
8. Pertwee, R.G., Cannabinoid receptors and pain. Prog. Neurobiol. 63 (2001), 569–611.
9. Terranova, J.-P., Storme, J.-J., Lafon, N., Pério, A., Rinaldi-Carmona, M., Le Fur, G., Soubrié, P., Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126 (1996), 165–172.
10. Lichtman, A.H., SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur. J. Pharmacol. 404 (2000), 175–179.
11. Pertwee, R.G., Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6 (1999), 635–664.
12. Auclair, N., Otani, S., Soubrié, P., Crepel, F., Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. 83 (2000), 3287–3293.
13. Gifford, A.N., Bruneus, M., Gatley, S.J., Volkow, N.D., Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br. J. Pharmacol. 131 (2000), 645–650.
14. 1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 363 (2001), 50–56.
15. Wilson, R.I., Nicoll, R.A., Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410 (2001), 588–592.
16. Huang, C.-C., Lo, S.-W., Hsu, K.-S., Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532 (2001), 731–748.
17. Ohno-Shosaku, T., Maejima, T., Kano, M., Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29 (2001), 729–738.
18. 1 cannabinoid receptors. Br. J. Pharmacol. 134 (2001), 161–167.
19. Fride, E., Ginzburg, Y., Breuer, A., Bisogno, T., Di Marzo, V., Mechoulam, R., Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur. J. Pharmacol. 419 (2001), 207–214.
20. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J.-P., Le Fur, G., Casellas, P., A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor: 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272 (1997), 22330–22339.
21. 2 receptors. Br. J. Pharmacol. 124 (1998), 619–622.
22. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 54 (1998), 1064–1072.
23. 1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. 459 (1999), 277–281.
24. McAllister, S.D., Griffin, G., Satin, L.S., Abood, M.E., Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. J. Pharmacol. Exp. Ther. 291 (1999), 618–626.
25. Rubino, T., Viganò, D., Zagato, E., Sala, M., Parolaro, D., In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 35 (2000), 8–14.
26. 1 cannabinoid receptor. Biochem. Pharmacol. 60 (2000), 1315–1323.
27. Ross, R.A., Coutts, A.A., McFarlane, S.M., Anavi-Goffer, S., Irving, A.J., Pertwee, R.G., MacEwan, D.J., Scott, R.H., Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40 (2001), 221–232.
28. Sim-Selley, L.J., Brunk, L.K., Selley, D.E., Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414 (2001), 135–143.
29. Breivogel, C.S., Griffin, G., Di Marzo, V., Martin, B.R., Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60 (2001), 155–163.
30. 1 receptors in guinea-pig small intestine. Br. J. Pharmacol. 118 (1996), 2199–2205.
31. 1 receptors in mouse urinary bladder. Br. J. Pharmacol. 118 (1996), 2053–2058.
32. 8-tetrahydrocannabinol in two isolated tissue preparations. Eur. J. Pharmacol. 315 (1996), 195–201.
33. 1 receptors. Br. J. Pharmacol. 124 (1998), 1363–1368.
34. Christopoulos, A., Coles, P., Lay, L., Lew, M.J., Angus, J.A., Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br. J. Pharmacol. 132 (2001), 1281–1291.
35. Begg, M., Molleman, A., Parsons, M., Modulation of the release of endogenous γ-aminobutyric acid by cannabinoids in the guinea pig ileum. Eur. J. Pharmacol. 434 (2002), 87–94.
36. 2 receptors. Pharmacol. Ther. 74 (1997), 129–180.
37. Schlicker, E., Kathmann, M., Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22 (2001), 565–572.
38. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg's Arch. Pharmacol. 356 (1997), 583–589.
39. Szabo, B., Dörner, L., Pfreundtner, C., Nörenberg, W., Starke, K., Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85 (1998), 395–403.
40. Katona, I., Sperlágh, B., Sik, A., Käfalvi, A., Vizi, E.S., Mackie, K., Freund, T.F., Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19 (1999), 4544–4558.
41. Pertwee, R.G., Ross, R.A., Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fat. Acids 66 (2002), 101–121.
42. Walker, J.M., Huang, S.M., Strangman, N.M., Tsou, K., Sañudo-Peña, M.C., Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 12198–12203.
43. Baker, D., Pryce, G., Croxford, J.L., Brown, P., Pertwee, R.G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., Di Marzo, V., Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15 (2001), 300–302.
44. Pertwee, R.G., Fernando, S.R., Griffin, G., Abadji, V., Makriyannis, A., Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol. 272 (1995), 73–78.
45. Kearn, C.S., Greenberg, M.J., DiCamelli, R., Kurzawa, K., Hillard, C.J., Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem. 72 (1999), 2379–2387.
46. Vásquez, C., Lewis, D.L., The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19 (1999), 9271–9280.
47. Nie, J., Lewis, D.L., Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J. Neurosci. 21 (2001), 8758–8764.
48. Colombo, G., Agabio, R., Lobina, C., Reali, R., Gessa, G.L., Cannabinoid modulation of intestinal propulsion in mice. Eur. J. Pharmacol. 344 (1998), 67–69.
49. 1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 359 (1999), 65–70.
50. Izzo, A.A., Mascolo, N., Pinto, L., Capasso, R., Capasso, F., The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur. J. Pharmacol. 384 (1999), 37–42.
51. Gessa, G.L., Mascia, M.S., Casu, M.A., Carta, G., Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur. J. Pharmacol. 327 (1997), R1–R2.
52. Gessa, G.L., Casu, M.A., Carta, G., Mascia, M.S., Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur. J. Pharmacol. 355 (1998), 119–124.
53. Hájos, N., Ledent, C., Freund, T.F., Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001), 1–4.
54. Járai, Z., Wagner, J.A., Varga, K., Lake, K.D., Compton, D.R., Martin, B.R., Zimmer, A.M., Bonner, T.I., Buckley, N.E., Mezey, E., Razdan, R.K., Zimmer, A., Kunos, G., Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 14136–14141.
55. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J.B., Finazzi-Agrò, A., Di Marzo, V., The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276 (2001), 12856–12863.
56. Lang, W., Qin, C., Lin, S., Khanolkar, A.D., Goutopoulos, A., Fan, P., Abouzid, K., Meng, Z., Biegel, D., Makriyannis, A., Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J. Med. Chem. 42 (1999), 896–902.
57. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sφrgård, M., Di Marzo, V., Julius, D., Högestätt, E.D., Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999), 452–457.
58. Chaytor, A.T., Martin, P.E.M., Evans, W.H., Randall, M.D., Griffith, T.M., The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J. Physiol. 520 (1999), 539–550.
59. White, R., Hiley, C.R., The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol. 125 (1998), 689–696.